Drug maker Lupin announced that it has received the new drug application (NDA) approval from the US health regulator to market its Suprax capsules in the strength of 400 mg in America.
Drug maker Lupin announced that it has received the new drug application (NDA) approval from the US health regulator to market its Suprax capsules in the strength of 400 mg in America.
Lupin Group President & ED Nilesh Gupta said: "The new dosage form will add to our growing Suprax franchise and gives healthcare providers and patients a new formulation to treat the indicated infections".
Source-Medindia